嵌合抗原受体自然杀伤细胞疗法:利用先天免疫的力量
本综述讨论CAR NK细胞疗法的临床前与临床试验进展及克服挑战的策略。CAR T细胞在难治性淋巴恶性肿瘤中疗效显著,但受细胞因子释放综合征、神经毒性、制造复杂性、成本、治疗等待时间及异体CAR-T的移植物抗宿主病风险限制。NK细胞因可及性和安全性成为CAR疗法有前景的细胞来源,可来自多种来源并经基因工程表达CAR。
要点
- CAR T细胞在难治性淋巴恶性肿瘤中疗效显著但受毒性、制造复杂性和成本限制。
- NK细胞因可及性和安全性成为CAR疗法有前景的细胞来源。
- CAR NK细胞临床前结果令人印象深刻,正于多项临床试验中探索。
核心结论
- CAR NK细胞疗法临床前结果令人印象深刻,并正在多项临床试验中探索。
研究设计与样本
- 综述,讨论CAR NK细胞疗法的临床前与临床试验进展及克服挑战的策略。
主要发现
- CAR T细胞在难治性淋巴恶性肿瘤中产生显著疗效。
- CAR T细胞的广泛临床使用受细胞因子释放综合征和神经毒性相关毒性限制。
- 自体CAR-T细胞受制造物流复杂性、成本及治疗等待时间限制。
- 异体CAR-T细胞存在移植物抗宿主病风险。
- NK细胞无需预先致敏即可产生细胞因子并介导细胞毒性,并能与其他免疫细胞相互作用并激活它们。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cells are a rapidly emerging form of cancer treatment, and have resulted in remarkable responses in refractory lymphoid malignancies. However, their widespread clinical use is limited by toxicity related to cytokine release syndrome and neurotoxicity, the logistic complexity of their manufacturing, cost and time-to-treatment for autologous CAR-T cells, and the risk of graft-versus-host disease (GvHD) associated with allogeneic CAR-T cells. Natural killer (NK) cells have emerged as a promising source of cells for CAR-based therapies due to their ready availability and safety profile. NK cells are part of the innate immune system, providing the first line of defence against pathogens and cancer cells. They produce cytokines and mediate cytotoxicity without the need for prior sensitisation and have the ability to interact with, and activate other immune cells. NK cells for immunotherapy can be generated from multiple sources, such as expanded autologous or allogeneic peripheral blood, umbilical cord blood, haematopoietic stem cells, induced pluripotent stem cells, as well as cell lines. Genetic engineering of NK cells to express a CAR has shown impressive preclinical results and is currently being explored in multiple clinical trials. In the present review, we discuss both the preclinical and clinical trial progress made in the field of CAR NK-cell therapy, and the strategies to overcome the challenges encountered.
引用
- Rafei H, Daher M, Rezvani K, et al. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br J Haematol. 2020. PMID: 33216984. doi:10.1111/bjh.17186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。